Skip to main content

Advertisement

Table 3 Correlation between VEGF and SEMA4D expression and clinicopathologic characteristics of EOC patients

From: VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer

Variable Cases (N) SEMA4D positive expression VEGF positive expression
n (%) p n (%) p
Age    0.078   0.431
  ≤ 50 years 60 32 (53.3)   23 (38.3)  
  > 50 years 64 44 (68.8)   29 (45.3)
Menopausal status    0.223   0.913
 Yes 78 51 (65.4)   33 (42.3)  
 No 46 25 (54.3)   19 (41.3)
Pathologic type    0.709   0.581
 Serous carcinoma 80 50 (62.5)   35 (43.8)  
 Mucous and others 44 26 (59.1)   17 (38.6)
Histologic grade    0.000   0.039
 G1-2 49 20 (40.8)   15 (30.6)  
 G3 or undifferentiated 75 56 (74.7)   37 (49.3)
FIGO Stage    0.016   0.000
 I–II 53 26 (49.1)   8 (15.1)  
 III–IV 71 50 (70.4)   44 (62.0)
LN metastasis    0.017   0.062
 No 74 39 (52.7)   26 (35.1)  
 Yes 50 37 (74.0)   26 (52.0)
Residual disease    0.004   0.304
  < 1 cm 94 51 (54.3)   37 (39.4)  
  ≥ 1 cm 30 25 (83.3)   15 (50.0)
Patients’ response to chemotherapy    0.349   0.010
 CR 87 51 (58.6)   30 (34.5)  
 PR, SD and PD 37 25 (67.6)   22 (59.5)
Tumor sensitivity to chemotherapy    0.315   0.006
 Platinum sensitive 92 54 (58.7)   32 (34.8)  
 Platinum resistant and refractory 32 22 (68.8)   20 (62.5)